The COVID-19 pandemic has challenged researchers worldwide, creating a common goal to understand the SARS-COV-2 virus, how to eradicate it, and how to prevent future coronavirus outbreaks. Rockland has a long-established history of providing critical antibodies and reagents as a qualified raw material supplier—specifically in the area of infectious disease and in vitro diagnostics.
Our antibodies specific to SARS-CoV-2 Nucleocapsid and Spike proteins are being used both directly and indirectly for vaccine development, drug discovery, diagnostics, and COVID-19 research by our global network of collaborators. Since the discovery of SARS-CoV-2, Rockland has been producing antibodies targeting various viral proteins, including the Membrane protein, 3CL Protease, and Non-Structural Protein 3 (NSP3) and 8 (NSP8).
Antibodies capable of detecting SARS-CoV-2
Due to high homology with the 2002 SARS-CoV, our existing antibodies have successfully detected the SARS-CoV-2 virus and assisted with the determination of host cells, such as Vero E6 cells, and the identification of the ACE2 receptor that binds SARS-CoV-2.
Rockland has also rapidly developed novel antibodies specific to SARS-CoV-2 using engineered immunogens. Our monoclonal antibodies generate highly specific immune responses to unique epitopes within SARS-CoV-2 proteins, distinguishable from other coronaviruses. Additionally, our polyclonal antibodies offer robust, consistent detection of viral proteins and their variants.
